Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 8/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | BCL2 | P10415 | 2/20 | 0.37 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.36 |
| ▸ | PTPRC | P08575 | 1/20 | 0.36 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.36 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13087364 | 0.89 | MCL1 (0.36) | MCL1SIGMAR1BCL2BCL2L1MKNK2 | |
| SCHEMBL3053722 | 0.83 | MCL1 (0.46) | MCL1SIGMAR1BCL2BCL2L1MKNK2 | |
| SCHEMBL3049690 | 0.83 | MCL1 (0.43) | MCL1BCL2BCL2L1MKNK2HDAC1 | |
| SCHEMBL2178672 | 0.78 | EGFR (0.44) | — | |
| SCHEMBL3057747 | 0.78 | POLB (0.56) | POLB | |
| SCHEMBL13087914 | 0.74 | MCL1 (0.40) | MCL1SIGMAR1BCL2BCL2L1MKNK2 | |
| SCHEMBL13087479 | 0.74 | MCL1 (0.42) | MCL1SIGMAR1BCL2BCL2L1MKNK2 | |
| SCHEMBL2180434 | 0.73 | CHEK1 (0.50) | — | |
| SCHEMBL3072266 | 0.71 | CHEK1 (0.39) | — | |
| SCHEMBL3072332 | 0.70 | AURKA (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261736-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | LAMPE THOMAS | 2010-10-14 | — | — | US | disclosed |
| EP-2167482-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | Bayer Schering Pharma AG (DE) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008155017-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261736-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE | HMGCR, PCSK9, FABP3 | MCL1 2397/4885SIGMAR1 3092/4885BCL2 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.